# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**WASHINGTON, D.C. 20549**

# FORM 8-K

**CURRENT REPORT**
**PURSUANT TO SECTION 13 OR 15(d) OF THE**
**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **March 26, 2026**

# DOGWOOD THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)

| **Delaware** | **001-39811** | **85-4314201** |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

| **44 Milton Avenue Alpharetta, GA** | **30009** |
|---|---|
| (Address of principal executive offices) | (Zip Code) |

Registrant's telephone number, including area code: **(866) 620-8655**

(Former name or former address, if changed since last report): N/A

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.0001 | DWTX | Nasdaq Capital Market |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On March 26, 2026, the Company posted a shareholder letter to its website providing a corporate update. A copy of the shareholder letter is furnished as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including the information in the shareholder letter attached as Exhibit 99.1 to this Current Report on Form 8-K is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

| Exhibit Number | Description |
|---|---|
| 99.1 | Shareholder letter, dated March 26, 2026 (furnished herewith). |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DOGWOOD THERAPEUTICS, INC.**

By: /s/ Angela Walsh
Name: Angela Walsh
Title: Chief Financial Officer, Corporate Secretary and Treasurer

March 26, 2026

## CEO Letter to Dogwood Therapeutics Shareholders: First Quarter 2026 Progress Report

ALPHARETTA, Ga., March 26, 2026 -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) ("DWTX" or "Company"), a development-stage biotechnology company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today issued a corporate update in the following Letter to Shareholders from CEO Greg Duncan.

Dear Shareholders,

Dogwood Therapeutics is a development-stage biotechnology company with the ultimate goal of advancing the standard of care for patients suffering from cancer-related pain and neuropathy, two conditions where both patients and providers are in clear need of alternative treatment options. As we exit the first quarter of 2026, the Company has made extensive progress over the past quarter in expanding and advancing its pipeline of first-in-class new development candidates to treat cancer- and chemotherapy-induced pain and neuropathy.

Highlights include:

- Recruitment of 145 patients in the Halneuron® Phase 2b Chemotherapy Induced Pain (HALT-CINP) Study, with final study data projected for release this fall.
- Raised $12.5 million in capital this quarter, which, when combined with our 2025 year-end cash on hand, provides operational runway through the Halneuron® HALT-CINP data release this fall.
- Filed the investigational new drug application for SP16 IV, a potential treatment for neuropathy and inflammation caused by cancer chemotherapy. The license is a royalty-free, global development and commercialization license to treat cancer-related pain and neuropathy.
    - The forthcoming SP16 Phase 1b study is fully funded by a development grant from the National Cancer Institute.
- Continued advanced development of a chemically equivalent, synthesized version of Halneuron® to be used for Phase 3 development and commercialization.
    - This new formulation should reduce manufacturing costs and improve yields as compared to the current biological extract.

As a team, we believe the year ahead holds great promise for DWTX shareholders and patients alike. In 2026, we are focused on executing on the following target milestones:

- Filing the SP16 Chemotherapy Induced Pain and Neuropathy Investigational New Drug application (IND) with FDA in collaboration with our partner, Serpin Pharma, in the first quarter.

- Commencing dosing patients in the forthcoming SP16 Phase 1b study by mid-2026.
- Full recruitment of the Halneuron® Phase 2b HALT-CINP study this summer.
- Submitting our end of Phase 2 summary, manufacturing plans and Phase 3 clinical development plans to FDA towards the end of 2026, assuming favorable outcomes in our ongoing Halneuron® Phase 2b program.

In closing, let me convey our appreciation for your support in our journey to advance the standard of care for patients suffering from pain and neuropathy. As always, we plan to communicate our corporate progress in a timely manner.

Sincerely,

Greg Duncan
Chairman & CEO of Dogwood Therapeutics, Inc.
March 2026

**About Dogwood Therapeutics:**

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV.

Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, $Na_V$ 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ("CINP"). SP16 IV is a low-density lipoprotein receptor related protein-1 agonist (LRP1) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial is fully funded by the National Cancer Institute.

Dogwood Therapeutic's largest shareholder is a member of CK Life Sciences Int'l., (Holdings) Inc., which is listed on the Hong Kong Stock Exchange (Stock code: 0775). For more information, please visit www.dwtx.com.

**Forward-Looking Statements:**

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will," “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2025, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

**Investor Relations:**

IR@dwtx.com